PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT03980938: Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
Official title: A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)
Conditions: Huntington Disease
Summary: This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD). The primary objective is to determine whether neflamapimod can reverse hippocampal dysfunction in patients with early-stage HD, as assessed by the virtual water-maze-test for evaluating spatial learning and selected tests on the Cambridge Neuropsychological Test Automated Battery (CANTAB).
Interventions:
description: 40 mg neflamapimod capsule
name: neflamapimod
other_name: VX-745
type: Drug
description: matching placebo capsule
name: Placebo
type: Other
Study arms:
design_group_description: neflamapimod in Treatment Period 1, placebo in Treatment Period 2<br/>neflamapimod: 40 mg neflamapimod hard gelatin capsules, taken twice daily with food.<br/>Placebo: hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.
design_group_title: neflamapimod first
design_group_type: Experimental
design_group_description: placebo in Treatment Period 1, neflamapimod in Treatment Period 2<br/>Placebo: hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.<br/>neflamapimod: 40 mg neflamapimod hard gelatin capsules, taken twice daily with food.
design_group_title: placebo first
design_group_type: Placebo Comparator
Sponsor: EIP Pharma, Inc.
Collaborators: Voisin Consulting, Inc.
Drug name mappings:
name: Neflamapimod
lang: EN
Clinical trial NCT01791309: Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer
Official title: A Pilot Study of Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer
Conditions: Metastatic Colorectal Cancer
Summary: The purpose of this study is to test a new drug combination consisting of two drugs, vemurafenib (also known as ZelborafTM) and panitumumab (also known as VectibixTM). This treatment is being tested in a subgroup of patients with colorectal cancer whose tumors have changes in the BRAF gene that may make them more likely to respond to this new drug combination.
Interventions:
description: Treatment will consist of panitumumab 6mg/kg IV every 14 days and vemurafenib 960mg orally twice daily. In patients who initially respond to treatment and later progress, a voluntary biopsy will be requested at the time of relapse to study mechanisms of acquired resistance. This biopsy should consist of at least one frozen core specimen. Every effort will be made to obtain this biopsy within 30 days of discontinuation of treatment and before the initiation of any new tumor-directed therapies.
name: combination panitumumab and vemurafenib
type: Drug
Study arms:
design_group_description: This will be a pilot study of the combination panitumumab and vemurafenib in patients with metastatic colorectal cancer with a BRAF V600E mutation. Patients participating in this study must have BRAF V600E mutated metastatic colorectal cancer and not previously received treatment with an anti-EGFR targeting antibody (cetuximab or panitumumab).
design_group_title: combination panitumumab and vemurafenib
design_group_type: Experimental
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: Genentech, Inc.
Drug name mappings:
name: 维莫非尼
lang: CN
name: Vemurafenib
lang: EN
name: ベムラフェニブ
lang: JP
name: 帕尼单抗
lang: CN
name: Panitumumab
lang: EN
name: パニツムマブ（遺伝子組換え）
lang: JP
Clinical trial NCT02232789: Abuse Liability and Human Pharmacology of Mephedrone
Official title: Abuse Liability and Human Pharmacology of Mephedrone (4-methylmethcathinone,4-MMC)
Conditions: Amphetamine-Related Disorders
Summary: The purposes of this study are 1) to evaluate the abuse liability and human pharmacology of mephedrone after oral administration and 2) to compare the pharmacological effects of mephedrone with those obtained after administration of oral 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
Interventions:
description: Single oral dose mephedrone
name: Mephedrone
other_name: 4-MMC
4-methylmethcathinone
type: Drug
description: Single oral dose MDMA
name: 3,4-methylenedioxymethamphetamine
other_name: Ecstasy
MDMA
type: Drug
description: Single oal dose placebo
name: Placebo
other_name: Non active treatment
type: Drug
Study arms:
design_group_description: Mephedrone 200 mg, single dose, oral administration
design_group_title: Mephedrone
design_group_type: Experimental
design_group_description: 3,4-methylenedioxymethamphetamine (MDMA) 100 mg, single dose, oral administration
design_group_title: 3,4-methylenedioxymethamphetamine
design_group_type: Active Comparator
design_group_description: Placebo, single dose, oral administration
design_group_title: Lactose
design_group_type: Placebo Comparator
Sponsor: Consorci Mar Parc de Salut de Barcelona
Collaborators: Instituto De SAlud Carlos Iii De Madrid
Drug name mappings:
name: 甲氧麻黄酮
lang: CN
name: Mephedrone
lang: EN
Clinical trial NCT00006098: PS-341 in Treating Patients With Hematologic Cancer
Official title: A Phase I Study of PS-341 in Patients With Hematologic Malignancies
Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Summary: RATIONALE: PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have hematologic cancer.
Interventions:
name: bortezomib
type: Drug
Study arms:
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: National Cancer Institute
Drug name mappings:
name: 硼替佐米
lang: CN
name: Bortezomib
lang: EN
name: ボルテゾミブ
lang: JP
Clinical trial NCT00278200: Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD
Official title: Vaccination of Patients at High Risk for Post-Transplant Lymphoproliferative Disorder With a Photochemically Inactivated EBV-Infected B-Cell Vaccine
Conditions: Lymphoproliferative Disorder
Summary: RATIONALE: Vaccines made from a person's white blood cells may help the body build an effective immune response.
PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients who are being considered for solid organ transplant who are at risk for post-transplant lymphoproliferative disorder.
Interventions:
name: Inactivated EBV-infected vaccine
type: Biological
Study arms:
design_group_description: Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were negative for Epstein-Barr Virus (EBV) at baseline.
design_group_title: EBV Seronegative
design_group_type: Experimental
design_group_description: Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were positive for Epstein-Barr Virus (EBV) at baseline.
design_group_title: EBV Seropositive
design_group_type: Experimental
Sponsor: The Sidney Kimmel Comprehensive Cancer Center
Collaborators: National Cancer Institute
Drug name mappings:
name: Inactivated EBV-infected vaccine(NCI)
lang: EN
Clinical trial NCT00930865: Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects
Official title: A Randomized, Open-Label, Parallel-group, Multiple-Dose Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects
Conditions: Type 2 Diabetes Mellitus
Summary: To assess the potential pharmacokinetic (PK) interactions of bumetanide and dapagliflozin following multiple doses of 1 mg bumetanide and 10 mg dapagliflozin in healthy subjects
Interventions:
description: Tablets, Oral, 1 mg, Single Dose, 7 Days
name: Bumetanide
other_name: Bumex
type: Drug
description: Tablets, Oral, 10 mg. Single Dose, 7 Days
name: Dapagliflozin
other_name: BMS-512148
type: Drug
Study arms:
design_group_title: Bumetanide
design_group_type: Active Comparator
design_group_title: Dapagliflozin
design_group_type: Active Comparator
design_group_title: Bumetanide + Dapagliflozin
design_group_type: Active Comparator
Sponsor: AstraZeneca PLC
Collaborators: Bristol Myers Squibb Co.
Drug name mappings:
name: 布美他尼
lang: CN
name: Bumetanide
lang: EN
name: ブメタニド
lang: JP
name: 达格列净
lang: CN
name: Dapagliflozin
lang: EN
name: ダパグリフロジンプロピレングリコール水和物
lang: JP
Clinical trial NCT01048580: Study of Perifosine + Capecitabine for Colon Cancer Patients
Official title: A Phase I Study of Perifosine + Capecitabine for Patients With Advanced Colon Cancer
Conditions: Colon Cancer
Summary: This is a Phase I study of Perifosine + Capecitabine for patients with advanced colon cancer.
Interventions:
description: Perifosine 50 mg orally once a day (Days 1-21)
name: Perifosine
other_name: D-21266
KRX-0401
type: Drug
description: Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)
name: Capecitabine
other_name: Xeloda
type: Drug
Study arms:
design_group_description: One cycle of therapy will be defined as 3 weeks (21 days). Perifosine 50 mg qd (Days 1-21) + Capecitabine 1000 mg/m2 BID (Days 1-14).
design_group_title: Perifosine +Capecitabine
design_group_type: Experimental
Sponsor: Æterna Zentaris, Inc.
Collaborators: Scri Development Innovations LLC
Drug name mappings:
name: 哌立福辛
lang: CN
name: Perifosine
lang: EN
name: 卡培他滨
lang: CN
name: Capecitabine
lang: EN
name: カペシタビン
lang: JP
Clinical trial NCT07250087: Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
Official title: Phase 1 Study of Asciminib Maintenance Therapy Following Allogeneic Stem Cell Transplant or Chimeric Antigen Receptor T Cell Therapy (CAR T) to Prevent Relapse in Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Summary: The purpose of the study is to see if a study drug called asciminib is safe and okay for people to take after they've had treatment for a type of blood cancer called Philadelphia Chromosome
Positive Acute Lymphoblastic Leukemia (Ph+ B-ALL). We're looking at two groups of adults:
one group had an Allogeneic Stem Cell Transplant (alloHCT) cohort A, and the other group had chimeric antigen receptor T cell (CAR T) therapy, cohort B. We also want to figure out what the best dose of asciminib is to use moving forward in future studies.
Interventions:
description: Treatment will be administered on an outpatient basis.
name: Asciminib
type: Drug
Study arms:
design_group_description: Individuals who have previously undergone an allogeneic stem cell transplant (alloHCT).
design_group_title: Patients post-alloHCT
design_group_type: Experimental
design_group_description: Individuals who have received chimeric antigen receptor T cell therapy (CAR T).
design_group_title: Patients post-CAR T cell therapy
design_group_type: Experimental
Sponsor: H. Lee Moffitt Cancer Center & Research Institute, Inc.
Collaborators: Novartis AG
Drug name mappings:
name: 盐酸阿思尼布
lang: CN
name: Asciminib Hydrochloride
lang: EN
name: アシミニブ塩酸塩
lang: JP
Clinical trial NCT01515969: Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)
Official title: A Phase I Study of Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer (NSCLC), Recurrent
Non-small Cell Lung Cancer (NSCLC), Stage IV
Summary: This phase I trial studies the side effects and best dose of giving erlotinib and dovitinib together to treat patients with metastatic non-small cell lung cancer. Erlotinib blocks the epidermal growth factor receptor (EGFR) and has known activity in non-small cell lung cancer and dovitinib blocks the fibroblast growth factor receptor (FGFR) and other targets which may be important to treat lung cancer. The combination of both drugs may work better than either drug alone, but may also have increased side effects. This trial will look at the side effects of combining the drugs and look for how effective the combination may be.
Interventions:
description: Given PO
name: Erlotinib hydrochloride
other_name: CP-358,774
Erlotinib HCl
OSI-774
Tarceva
type: Drug
description: Given PO
name: Dovitinib lactate
other_name: CHIR-258
Receptor tyrosine kinase (RTK) inhibitor TKI258
TKI258
type: Drug
Study arms:
design_group_description: Patients receive erlotinib hydrochloride PO QD. Starting on day 15, patients also receive dovitinib lactate PO QD on days 1-5 of each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
design_group_title: Treatment (enzyme inhibitor therapy)
design_group_type: Experimental
Sponsor: Stanford University
Collaborators: Genentech, Inc.
Novartis AG
Drug name mappings:
name: 盐酸厄洛替尼
lang: CN
name: Erlotinib Hydrochloride
lang: EN
name: エルロチニブ塩酸塩
lang: JP
name: 多维替尼乳酸盐
lang: CN
name: Dovitinib
lang: EN
Clinical trial NCT01682616: A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Official title: A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Conditions: Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Summary: This is a Phase 1b, open-label, multicenter study evaluating the safety and tolerability of ABT-199 in combination with rituximab in up to 50 subjects with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. The primary objectives of this study are to assess the safety profile, to determine the maximum tolerated dose and establish the Recommended Phase Two Dose of ABT-199 when administered in combination with rituximab. The dose escalation portion of the study will include approximately 30 subjects. Once the recommended phase two dose and schedule have been determined, up to 20 additional subjects will be enrolled in an expanded safety portion of the study. Subjects who meet criteria for CR, CRi, or MRD-negative PR during the study may discontinue ABT 199. If disease progression occurs, as defined by iwCLL NCI/WG criteria for tumor response, or MRD progression, subjects may re-initiate ABT-199.
Interventions:
description: ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
name: ABT-199
other_name: venetoclax
type: Drug
description: Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.
name: Rituximab
type: Drug
Study arms:
design_group_description: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
design_group_title: Arm 1
design_group_type: Experimental
Sponsor: AbbVie, Inc.
Collaborators: Genentech, Inc.
Drug name mappings:
name: 维奈克拉
lang: CN
name: Venetoclax
lang: EN
name: ベネトクラクス
lang: JP
name: 利妥昔单抗
lang: CN
name: Rituximab
lang: EN
name: リツキシマブ（遺伝子組換え）
lang: JP
Clinical trial NCT01507402: A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)
Conditions: Healthy Volunteers
Summary: This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of Intravenous (IV) and Subcutaneous (SC) REGN1033(SAR391786) in healthy volunteers.
Interventions:
description: Administration method A
name: REGN1033(SAR391786)
type: Drug
description: Administration method B
name: REGN1033(SAR391786)
type: Drug
description: (inactive substance)
name: Placebo
type: Drug
Study arms:
design_group_description: Dose regimen 1 (Participants 18 to ≤ 65 yrs old)
design_group_title: Cohort 1
design_group_type: Experimental
design_group_description: Dose regimen 2 (Participants 18 to ≤ 65 yrs old)
design_group_title: Cohort 2
design_group_type: Experimental
design_group_description: Dose regimen 3 (Participants 18 to ≤ 65 yrs old)
design_group_title: Cohort 3
design_group_type: Experimental
design_group_description: Dose regimen 4 (Participants 18 to ≤ 65 yrs old)
design_group_title: Cohort 4
design_group_type: Experimental
design_group_description: Dose regimen 5 (Participants 18 to ≤ 65 yrs old)
design_group_title: Cohort 5
design_group_type: Experimental
design_group_description: Dose regimen 6 (Participants 18 to ≤ 65 yrs old)
design_group_title: Cohort 6
design_group_type: Experimental
design_group_description: Dose regimen 7 (Participants 18 to ≤ 65 yrs old)
design_group_title: Cohort 7
design_group_type: Experimental
design_group_description: Dose regimen 3 (Participants > 65 to ≤ 85 yrs old)
design_group_title: Cohort 8
design_group_type: Experimental
design_group_description: Dose regimen 9 (Participants 18 to ≤ 65 yrs old)
design_group_title: Cohort 9
design_group_type: Experimental
Sponsor: Regeneron Pharmaceuticals, Inc.
Collaborators: Sanofi
Drug name mappings:
name: Trevogrumab
lang: EN
Clinical trial NCT02049593: PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Official title: Phase I Trial of BMN 673 and Selected Cytotoxics in Patients With Advanced Solid Tumors
Conditions: Metastatic Cancer
Unspecified Adult Solid Tumor
Summary: This phase I trial studies the side effects and the best dose of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor BMN-673 when given together with temozolomide or irinotecan hydrochloride in treating patients with locally advanced or metastatic solid tumors. PARP inhibitor BMN-673 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help temozolomide and irinotecan hydrochloride work better by making tumor cells more sensitive to the drug. Drugs used in chemotherapy, such as temozolomide and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving PARP inhibitor BMN-673 with temozolomide or irinotecan hydrochloride may be an effective treatment for patients with advanced solid tumors.
Interventions:
description: Given PO
name: PARP inhibitor BMN-673
other_name: BMN 673
BMN-673
type: Drug
description: Given PO
name: temozolomide
other_name: SCH 52365
TMZ
Temodal
Temodar
type: Drug
description: Given IV
name: irinotecan hydrochloride
other_name: CPT-11
Campto
Camptosar
U-101440E
irinotecan
type: Drug
description: Correlative studies
name: pharmacological study
other_name: pharmacological studies
type: Other
description: Correlative studies
name: laboratory biomarker analysis
type: Other
Study arms:
design_group_description: Patients receive PARP inhibitor BMN-673 PO QD on days 1-28 and temozolomide PO daily on days1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
design_group_title: Arm A (PARP inhibitor BMN-673, temozolomide)
design_group_type: Experimental
design_group_description: Patients receive PARP inhibitor BNM-673 as in Arm A and irinotecan hydrochloride IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
design_group_title: Arm B (PARP inhibitor BMN-673, irinotecan hydrochloride)
design_group_type: Experimental
Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: Translational Research In Oncology
BioMarin Pharmaceutical, Inc.
MediVation, Inc.
Drug name mappings:
name: 替莫唑胺
lang: CN
name: Temozolomide
lang: EN
name: テモゾロミド
lang: JP
name: 甲苯磺酸他拉唑帕利
lang: CN
name: Talazoparib Tosylate
lang: EN
name: タラゾパリブトシル酸塩
lang: JP
name: 盐酸伊立替康
lang: CN
name: Irinotecan Hydrochloride
lang: EN
name: イリノテカン塩酸塩水和物
lang: JP
Clinical trial NCT06463184: Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)
Official title: A Phase 1, Open-Label Window-of-Opportunity Study to Assess the Pharmacokinetics, Pharmacodynamics and Central Nervous System (CNS) Penetration of Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)
Conditions: Recurrent High-grade Glioma
Summary: Researchers will investigate the ability of Xevinapant to cross the blood-brain barrier and exert anti-tumor effects on rHGG through activation of apoptosis. Researchers hypothesize that oral administration of Xevinapant has acceptable safety and tolerability in patients with recurrent HGG and demonstrate pharmacokinetic and pharmacodynamic effects in HGG tumors. To that end, Researchers will engage in a phase I "window of opportunity" translational clinical trial in patients undergoing a clinically-indicated craniotomy for resection of recurrent tumors to evaluate the impact of treatment on rHGG.
Interventions:
description: Xevinapant is an investigational medication, taken orally, that promotes cancer cell death via apoptosis.
name: Xevinapant
other_name: Debio 1143
type: Drug
Study arms:
design_group_description: Participants will be given a course of orally administered Xevinapant at 400 mg once daily for 4 consecutive days, prior to undergoing clinically indicated tumor resection.
design_group_title: Xevinapant Treatment
design_group_type: Experimental
Sponsor: H. Lee Moffitt Cancer Center & Research Institute, Inc.
Collaborators: EMD Serono Research & Development Institute, Inc.
Drug name mappings:
name: Xevinapant
lang: EN
Clinical trial NCT03665454: PF 06412562 in Subjects With Advanced Stage Parkinson's Disease
Official title: A Phase Ib Safety, Tolerability, and Efficacy Study of Two Days of Oral Split Dose (25/20 mg) Administration of PF 06412562 in Subjects With Advanced Stage Parkinson's Disease
Conditions: Parkinson Disease
Summary: The purpose of this study is to test the safety and tolerability of the investigational drug PF-06412562 compared to the current medical standard of care medication for Parkinson's disease, carbidopa/levodopa. This research also is being done to find out if the investigational drug PF-06412562 can help improve the motor (movement) function, alertness, and cognitive (thinking) skills of people who are considered to be in the advanced-stage of Parkinson's disease. In this study, PF06412562 is 'investigational,' which means that it is experimental and has not been approved by the US Food and Drug Administration (FDA), but can be used in clinical research studies such as this one.
Interventions:
description: PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.
name: PF-06412562
type: Drug
description: 25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
name: Standard of Care Placebo
other_name: Sinemet
type: Drug
Study arms:
design_group_description: Subjects will receive 25 mg of PF-06412562 twice daily on study Days 2 and 3, along with placebo carbidopa/levodopa dosed at these times. Additional carbidopa/levodopa placebo capsules also will be administered according to the subject's home regimen.
design_group_title: PF-06412562
design_group_type: Experimental
design_group_description: Subjects will take placebo tablets for the PF-06412562 twice daily on study Days 2 and 3, along with active carbidopa/levodopa (25/100 mg) administered at these times. Additional active carbidopa/levodopa capsules also will be administered according to the subject's home regimen.
design_group_title: Standard of Care carbidopa/levodopa
design_group_type: Active Comparator
Sponsor: Hershey Medical Center
Collaborators: Pfizer Inc.
Drug name mappings:
name: PF-06412562
lang: EN